Fulgent Genetics, Inc. (FLGT) News

Fulgent Genetics, Inc. (FLGT): $57.98

2.08 (+3.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter FLGT News Items

FLGT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FLGT News Highlights

  • For FLGT, its 30 day story count is now at 30.
  • Over the past 29 days, the trend for FLGT's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
  • RARE, NGS and BBW are the most mentioned tickers in articles about FLGT.

Latest FLGT News From Around the Web

Below are the latest news stories about Fulgent Genetics Inc that investors may wish to consider to help them evaluate FLGT as an investment opportunity.

Fulgent, Epic Sciences collaborate on test for metastatic breast cancer

Epic Sciences is collaborating with Fulgent Genetics (FLGT -5.9%) to deliver DefineMBC profiling results for patients with metastatic breast cancer (MBC). The partnership links Fulgent's CAP/CLIA certified next generation sequencing services with Epic's cell analysis platform as part of Epic's novel DefineMBC liquid biopsy test. The companies said the DefineMBC includes...

Seeking Alpha | February 24, 2022

EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS

Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent's leading CAP/CLIA certified Next Generation Sequencing services with Epic's best-in-class cell analysis platform as part of Epic's novel DefineMBC liquid biopsy test.

Yahoo | February 24, 2022

Fulgent Genetics Non-GAAP EPS of $3.48 beats by $0.81, revenue of $251.7M beats by $60.6M

Fulgent Genetics press release (NASDAQ:FLGT): Q4 Non-GAAP EPS of $3.48 beats by $0.81. Revenue of $251.7M beats by $60.6M. Shares -5%. Outlook Q1 2022:T otal Revenue of approximately $245 million; Core Revenue including COVID-19 NGS of approximately $32 million, representing growth of 92% year-over-year; Core Revenue excluding COVID-19 NGS of approximately $22 million...

Seeking Alpha | February 23, 2022

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q4 2021 Results - Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q4 2021 Earnings Conference Call February 23, 2022 04:30 PM ET Company Participants Nicole Borsje - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Larry Weiss - Chief Medical Officer Conference Call Participants Kevin...

SA Transcripts on Seeking Alpha | February 23, 2022

Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics,” “Fulgent,” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Results: Revenue of $251.7 million Billable tests delivered approximately 2.5 million Core Revenue grew 234%

Business Wire | February 23, 2022

Fulgent Genetics stock drops 12% after hours despite beats on top and bottom lines (FLGT)

Shares of Fulgent Genetics (FLGT) are down 12% in after-hours trading despite quarterly results that beat on the top and bottom lines.

Seeking Alpha | February 23, 2022

Fulgent Genetics, Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 23, 2022

Fulgent Genetics invests $40M in Spatial Genomics'' series A funding round

Fulgent Genetics (FLGT) announced a strategic investment in Spatial Genomics.FLGT is investing up to $40M to lead Spatial''s series A financing, which totals ~$56M

Seeking Alpha | February 23, 2022

Fulgent Genetics, Inc. (FLGT) Q4 2021 Earnings Call Transcript

FLGT earnings call for the period ending December 31, 2021.

The Motley Fool | February 23, 2022

Fulgent Genetics Announces Strategic Investment in Spatial Genomics

TEMPLE CITY, Calif. & PASADENA, Calif., February 23, 2022--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. ("Spatial"), a leading developer of sequential fluorescence in situ hybridization (seqFISH) technology. Fulgent Genetics is investing up to $40 million to lead

Yahoo | February 23, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4734 seconds.